At the news
? NEUTRALIMPACT 2/10 8-K filed Sep 16, 2026 at 09:12 ET
Alkermes appointed Anne C. Whitaker as an independent director, expanding the board from 10 to 11 members. Ms. Whitaker is a seasoned biopharmaceutical executive with prior CEO experience and current board seats at ICON plc and Basilea Pharmaceutica. The filing is a routine board appointment with no material financial impact, no financial results, guidance, or strategic changes were disclosed.
- Board expanded from 10 to 11 directors with the appointment of Anne C. Whitaker.
- Ms. Whitaker will receive an initial equity award with an aggregate target value of $600,000, split 50% stock options and 50% RSUs, vesting over three years.
- Ms. Whitaker is an independent director with no prior transactions with the company since January 1, 2025.
- The appointment is effective September 14, 2026, with a term expiring at the 2027 annual general meeting.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access